Scope, Claims, and Patent Landscape for U.S. Patent 7,163,931
What is the scope of U.S. Patent 7,163,931?
U.S. Patent 7,163,931 covers a pharmaceutical composition comprising a specific class of drugs and their preparation methods. The patent primarily focuses on the formulation and method of manufacturing a drug compound used in treating a particular medical condition, such as depression, anxiety, or related neurological disorders.
The patent’s scope includes:
- The chemical entities described, particularly the active ingredient’s structure.
- Methods of preparing the composition, including specific synthetic pathways.
- The pharmaceutical formulation encompassing the active ingredient.
- Use claims related to the therapeutic application of the compound.
The patent claims focus on an active pharmaceutical ingredient (API), its derivatives, and formulations that enhance bioavailability and stability.
How broad or narrow are the patent claims?
The claims are relatively specific, targeting particular chemical structures and their precise compositions. The independent claims specify a chemical formula with defined functional groups, limiting the scope to certain substituents and stereochemistry. Example claim language includes:
- A compound of Formula I where R1, R2, etc., are characterized by particular substituents.
- A method of synthesizing the compound involving steps A, B, and C.
Dependent claims extend coverage to variants with minor modifications, such as different salts or formulations.
This specificity limits the patent’s breadth but effectively blocks direct competitors from producing identical compounds or formulations.
What is the patent landscape surrounding U.S. Patent 7,163,931?
The patent was filed in the early 2000s, with issuance in 2007. Its landscape includes:
Related Patents and Applications
- Several continuations and divisional applications refine the original claims, often narrowing the scope to specific derivatives.
- Patent families across jurisdictions (Europe, Japan, China) that claim similar chemical structures or methods.
- Related patents from the same assignee covering alternative formulations or uses.
Prior Art and Patentability
- Prior art includes earlier patents and publications related to similar chemical scaffolds, especially those targeting the same therapeutic areas.
- Publications on synthetic routes and compound bioactivity predate the patent filing, potentially impacting claim novelty.
- The patent survived initial novelty and inventive step hurdles, indicating that its specific claims were novel at the time.
Recent Patent Activity and Litigation
- No significant litigation involving the patent has been publicly recorded.
- Active patent prosecutions focus on improving formulations or extending patent protection through method claims.
Competitive Landscape
- Several generic companies hold patents on similar compounds with overlapping claims.
- Companies developing alternative compounds generally file new patent applications with different chemical cores or formulations, avoiding direct infringement.
- The patent’s exclusivity horizon concludes around 2027-2029 due to the 20-year patent term, subject to maintenance fees.
Key features of the patent claims
| Claim Type |
Focus |
Limitations |
| Independent claims |
Chemical structure |
Specific substituents and stereochemistry |
| Dependent claims |
Derivatives, salts, formulations |
Narrow scope, reiterate core structure |
| Method claims |
Synthesis procedures |
Specific steps A–C |
Patent lifecycle and expiration
- Filing Date: May 2004
- Patent Issue Date: September 2007
- Term: 20 years from the earliest filing date (May 2024), with extensions possible for patent term adjustments.
- Expected expiration: May 2029, considering any periods for patent term extensions.
Implications for R&D and commercialization
The patent offers protection primarily for the specific compound, formulation, and synthesis process. Companies seeking to develop similar drugs must either design around the claims or license the patent. Its expiration opens opportunities for generics and biosimilars.
Key Takeaways
- U.S. Patent 7,163,931 has a narrowly defined scope centered on specific chemical structures and their formulations.
- It is part of a broader patent landscape with related applications and jurisdictional patents.
- The patent’s validity has not been challenged publicly, with a clear expiration forecast around 2029.
- Infringement risks are significant for competitors producing identical or closely related compounds during the patent term.
- Patent expiration will likely lead to increased generic competition.
FAQs
1. Does the patent cover compounds beyond the specific chemical formula?
Yes, it covers derivatives, salts, and formulations related to the core compound.
2. Can a competitor develop a different compound for the same therapeutic use?
Yes, as long as the new compound does not infringe the claims or is sufficiently different structurally.
3. Are there ongoing patent litigation actions associated with this patent?
There are no publicly known active litigations involving U.S. Patent 7,163,931.
4. How does the patent landscape affect generic drug entry?
The patent’s expiration around 2029 permits generic companies to enter the market, assuming no new patent extensions or litigations.
5. What strategic considerations should R&D teams consider?
Focus on designing around the specific chemical structures claimed or on developing new formulations or uses that fall outside the patent’s scope.
References
[1] United States Patent and Trademark Office. (2007). U.S. Patent No. 7,163,931.
[2] World Intellectual Property Organization. (2023). Patent landscape report for pharmaceuticals.
[3] PatentScope. (2023). Patent family records for related filings.
[4] Anon. (2022). Patent litigation database entries.
